Cytotoxic Activity by a Pentacyclic Triterpenes-Rich Fraction from Tabebuia hypoleuca (C. Wright) Urb. on Cancer Cell Lines

SÁNCHEZ PERERA LM; BARAVALLE ME; RENNA M.S; OLMOS NICOTRA F; MONTEIRO KARIN M; REGALADO VELOZ AI; ORTEGA HH

EC PHARMACOLOGY AND TOXICOLOGY

ECronicom

Año: 2021

2453-188X

Tabebuia genus has traditionally medicinal properties. Recently, we reported the antitumor activity on some tumor human cells from leaves of Tabebuia hypoleuca. The aim of this work was evaluated specificity of cytotoxic activity and apoptosis against cancer cell lines, acute toxicity and genotoxicity on micronucleus from clean ethyl acetate crude, triterpenes fraction isolated of Tabebuia hypoleuca leaves. In vitro cytotoxic activity was evaluated on human cancer cell lines: HT29 (colon), A549 (lung adenocarcinoma), Hep2 (epidermoid carcinoma), SK-MEL 28 (skin malign melanoma); mice cancer cell: F3II (murine breast carcinoma) and VERO (monkey kidney normal cells) using crystal violet. Annexin V and Propidium Iodide were used to determinate the apoptosis and/or necrosis induction from this active fraction on A549, F3II, HT29 and VERO cells. Oral acute toxicity at 500 mg/Kg of this fraction and genotoxicity (micronucleus) were evaluated. Pentacyclic triterpenes fraction had potent cytotoxic activity with all tumor cells used and some selectivity index respect to VERO cells. Anticancer activity were shown by apoptosis induction in the cell lines, with 94% induction in HT29, 89% in F3II, 74% in A549 and 55% in VERO cells, showing selectivity against normal cells. Active fraction was not toxic in acute toxicity and genotoxicity studies. These studies showed the effectiveness and security from pentacyclic triterpenes fraction from T. hypoleuca as anticancer pharmaceutical ingredient.